• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

12-17 岁青少年接种辉瑞-生物科技（BNT162b2）信使核糖核酸 COVID-19 疫苗的安全性：系统评价和荟萃分析。

Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.

机构信息

Office of the President and CEO, South African Medical Research Council, Cape Town, South Africa.

Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

出版信息

Hum Vaccin Immunother. 2022 Nov 30;18(6):2144039. doi: 10.1080/21645515.2022.2144039. Epub 2022 Nov 11.

DOI:10.1080/21645515.2022.2144039
PMID:36367429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9746476/
Abstract

The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model meta-analysis to derive pooled rates of single or grouped adverse events following immunization (AEFI) after each primary and booster dose, as well as after combining all doses. Reporting on over one million participants with safety data were included. The most-reported local and systemic AEFIs were pain/swelling/erythema/redness and fatigue/headache/myalgia, respectively. AESIs were rarely reported but were more frequent after the second dose than they were after the first and the booster doses. Health impact was less common among adolescents after receiving BNT162b2 vaccine. Rare life-threatening AEFIs were reported across all doses in real-world studies. Our findings highlight the significance of enhancing national and regional vaccination programs to ensure public confidence.

摘要

COVID-19 大流行严重影响了青少年。安全有效的疫苗是控制这一大流行病的关键工具。我们使用主要是真实世界的数据来审查 BNT162b2 COVID-19 疫苗在青少年中的安全性概况，以协助决策。我们使用随机效应模型荟萃分析得出每次基础和加强剂量以及所有剂量组合后，接种后单一或分组不良事件（AEFI）的累积发生率。报告了超过 100 万名具有安全性数据的参与者。报告最多的局部和全身 AEFI 分别为疼痛/肿胀/红斑/发红和疲劳/头痛/肌痛。AEFI 很少报告，但在第二剂后比第一剂和加强剂后更常见。接受 BNT162b2 疫苗接种后，青少年的健康影响较少。在真实世界研究中，所有剂量均报告了罕见的危及生命的 AEFI。我们的研究结果强调了加强国家和区域疫苗接种计划以确保公众信心的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/0f5db42a16b3/KHVI_A_2144039_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/730cd88e6e60/KHVI_A_2144039_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/2e252cbbe7a6/KHVI_A_2144039_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/cd25a43a9f5f/KHVI_A_2144039_F0003a_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/1a7014e6c53a/KHVI_A_2144039_F0003b_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/fa9075aadd83/KHVI_A_2144039_F0003c_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/f18461bf5688/KHVI_A_2144039_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/62e450e99d0d/KHVI_A_2144039_F0005a_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/076801ba52b5/KHVI_A_2144039_F0005b_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/d4b35161ce7d/KHVI_A_2144039_F0005c_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/0f5db42a16b3/KHVI_A_2144039_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/730cd88e6e60/KHVI_A_2144039_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/2e252cbbe7a6/KHVI_A_2144039_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/cd25a43a9f5f/KHVI_A_2144039_F0003a_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/1a7014e6c53a/KHVI_A_2144039_F0003b_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/fa9075aadd83/KHVI_A_2144039_F0003c_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/f18461bf5688/KHVI_A_2144039_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/62e450e99d0d/KHVI_A_2144039_F0005a_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/076801ba52b5/KHVI_A_2144039_F0005b_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/d4b35161ce7d/KHVI_A_2144039_F0005c_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33c/9746476/0f5db42a16b3/KHVI_A_2144039_F0006_OC.jpg

相似文献

1
Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.12-17 岁青少年接种辉瑞-生物科技（BNT162b2）信使核糖核酸 COVID-19 疫苗的安全性：系统评价和荟萃分析。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2144039. doi: 10.1080/21645515.2022.2144039. Epub 2022 Nov 11.
2
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.2022 年 8 月 31 日至 10 月 23 日，12 岁及以上人群中双价 COVID-19 mRNA 疫苗加强针的安全性监测-美国。
MMWR Morb Mortal Wkly Rep. 2022 Nov 4;71(44):1401-1406. doi: 10.15585/mmwr.mm7144a3.
3
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.英国 ChAdOx1（牛津-阿斯利康）和 BNT162b2（辉瑞-生物科技）COVID-19 疫苗不良神经和精神反应的不均衡分析。
Expert Opin Drug Saf. 2023 Apr;22(4):343-349. doi: 10.1080/14740338.2022.2120607. Epub 2022 Sep 7.
4
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.12-17 岁人群 COVID-19 疫苗加强针接种的安全性监测 - 美国，2021 年 12 月 9 日-2022 年 2 月 20 日。
MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):347-351. doi: 10.15585/mmwr.mm7109e2.
5
Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.川崎病病史患者对 COVID-19 感染和信使 RNA 疫苗接种的耐受性。
JAMA Netw Open. 2022 Aug 1;5(8):e2226236. doi: 10.1001/jamanetworkopen.2022.26236.
6
Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.贝鲁特大学社区报告的辉瑞/生物新技术（BNT162b2） COVID-19 疫苗的副作用。
BMC Infect Dis. 2023 Jan 5;23(1):5. doi: 10.1186/s12879-022-07974-3.
7
Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.辉瑞-BioNTech COVID-19 疫苗加强针在 5-11 岁儿童中的安全性监测 - 美国，2022 年 5 月 17 日至 7 月 31 日。
MMWR Morb Mortal Wkly Rep. 2022 Aug 19;71(33):1047-1051. doi: 10.15585/mmwr.mm7133a3.
8
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.COVID-19 疫苗加强针接种后的安全性监测-美国，2021 年 9 月 22 日-2022 年 2 月 6 日。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. doi: 10.15585/mmwr.mm7107e1.
9
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用：来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
10
Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.美国 COVID-19 疫苗的不良事件：时空分析。
JMIR Public Health Surveill. 2024 Jul 15;10:e51007. doi: 10.2196/51007.

引用本文的文献

1
Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.对其他疫苗中使用的基孔肯雅热疫苗平台安全性的综合评价。
Hum Vaccin Immunother. 2025 Dec;21(1):2463191. doi: 10.1080/21645515.2025.2463191. Epub 2025 Feb 11.
2
Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.妊娠期 COVID-19 疫苗的安全性和有效性：一项实时系统评价和荟萃分析。
Drug Saf. 2024 Oct;47(10):991-1010. doi: 10.1007/s40264-024-01458-w. Epub 2024 Jul 15.
3
Evidence linking COVID-19 and the health/well-being of children and adolescents: an umbrella review.

本文引用的文献

1
Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data.青少年新冠疫苗的不良事件与安全性概况：利用真实世界数据对不良事件进行安全监测
Vaccines (Basel). 2022 May 9;10(5):744. doi: 10.3390/vaccines10050744.
2
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.SARS-CoV-2 感染和 mRNA COVID-19 疫苗接种后的心脏并发症 - PCORnet，美国，2021 年 1 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 8;71(14):517-523. doi: 10.15585/mmwr.mm7114e1.
3
Predictors of COVID-19 Vaccine Hesitancy in South African Local Communities: The VaxScenes Study.
将 COVID-19 与儿童和青少年健康/福祉联系起来的证据：伞式综述。
BMC Med. 2024 Mar 13;22(1):116. doi: 10.1186/s12916-024-03334-x.
4
COVID-19 Vaccine Perspective From Adolescents' Lens in the US.美国青少年视角下的新冠疫苗观
Cureus. 2024 Feb 4;16(2):e53566. doi: 10.7759/cureus.53566. eCollection 2024 Feb.
5
Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.12-17 岁青少年人群中 COVID-19 辉瑞-生物科技（BNT162b2）mRNA 疫苗接种的有效性：系统评价和荟萃分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2214495. doi: 10.1080/21645515.2023.2214495. Epub 2023 Jun 5.
6
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.SCB-2019 是一种含佐剂的、重组新型冠状病毒刺突蛋白三聚体亚单位 COVID-19 疫苗，在健康的 12-17 岁青少年中的安全性和免疫原性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206359. doi: 10.1080/21645515.2023.2206359. Epub 2023 May 25.
7
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.儿童和青少年接种 mRNA COVID-19 疫苗后的过敏反应发生率：EudraVigilance 报告数据的分析。
Vaccine. 2023 Mar 31;41(14):2382-2386. doi: 10.1016/j.vaccine.2023.02.067. Epub 2023 Feb 27.
南非当地社区新冠疫苗犹豫的预测因素：VaxScenes研究
Vaccines (Basel). 2022 Feb 25;10(3):353. doi: 10.3390/vaccines10030353.
4
Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study.使用 BNT162b2 后青少年特别关注的不良事件：基于人群的回顾性队列研究。
Emerg Microbes Infect. 2022 Dec;11(1):885-893. doi: 10.1080/22221751.2022.2050952.
5
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.12-17 岁人群 COVID-19 疫苗加强针接种的安全性监测 - 美国，2021 年 12 月 9 日-2022 年 2 月 20 日。
MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):347-351. doi: 10.15585/mmwr.mm7109e2.
6
Parents' and Guardians' Willingness to Vaccinate Their Children against COVID-19: A Systematic Review and Meta-Analysis.父母及监护人让其子女接种新冠疫苗的意愿：一项系统评价与荟萃分析
Vaccines (Basel). 2022 Jan 24;10(2):179. doi: 10.3390/vaccines10020179.
7
Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study.南非首次出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎（B.1.1.529）变异株疫情期间因新冠病毒病住院的儿童：一项多中心观察性研究
Lancet Child Adolesc Health. 2022 May;6(5):294-302. doi: 10.1016/S2352-4642(22)00027-X. Epub 2022 Feb 18.
8
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19.儿童多系统炎症综合征和儿童 COVID-19 的免疫病理特征。
Nat Med. 2022 May;28(5):1050-1062. doi: 10.1038/s41591-022-01724-3. Epub 2022 Feb 17.
9
Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study.SARS-CoV-2 感染（长新冠）后 3 个月青少年的身心健康（CLoCk）：一项全国匹配队列研究。
Lancet Child Adolesc Health. 2022 Apr;6(4):230-239. doi: 10.1016/S2352-4642(22)00022-0. Epub 2022 Feb 8.
10
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.日本对 BNT162b2 和 mRNA-1273 mRNA COVID-19 疫苗的不良反应。
J Infect Chemother. 2022 Apr;28(4):576-581. doi: 10.1016/j.jiac.2021.12.034. Epub 2022 Jan 11.